Saturna Capital Corp Buys 31,143 Shares of AbbVie Inc. $ABBV

Saturna Capital Corp lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 4.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 780,291 shares of the company’s stock after purchasing an additional 31,143 shares during the quarter. AbbVie comprises approximately 2.3% of Saturna Capital Corp’s holdings, making the stock its 13th biggest position. Saturna Capital Corp’s holdings in AbbVie were worth $178,289,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Chelsea Counsel Co. bought a new position in shares of AbbVie during the 3rd quarter worth approximately $26,000. Westend Capital Management LLC bought a new stake in AbbVie in the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX bought a new stake in AbbVie in the 3rd quarter valued at $31,000. Legacy Wealth Managment LLC ID boosted its stake in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the period. Finally, WestEnd Advisors LLC boosted its stake in AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Price Performance

Shares of NYSE ABBV opened at $225.16 on Thursday. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The stock has a market capitalization of $397.82 billion, a PE ratio of 110.92, a P/E/G ratio of 0.69 and a beta of 0.32. The business has a fifty day moving average price of $210.64 and a two-hundred day moving average price of $219.09.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.46 EPS. On average, equities analysts expect that AbbVie Inc. will post 14.3 EPS for the current year.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s migraine drug was cleared for use in migraine attacks on the NHS, a sign of broader adoption potential that could support future sales growth. AbbVie’s migraine drug cleared for migraine attacks on NHS
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, highlighted new consumer research in its aesthetics business, reinforcing ongoing brand visibility and interest in its aesthetics portfolio. Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’
• Neutral Sentiment: AbbVie presented at Goldman Sachs’ healthcare conference, which typically provides investors with updates on strategy and pipeline but did not include a major new catalyst in the headline. AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: AbbVie was mentioned in “final trades” and “below fair value”/discount-stock roundups, which may keep valuation-focused investors interested but are not company-specific operational news. Final trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
• Negative Sentiment: AbbVie received a Complete Response Letter from the FDA for TrenibotE, its fast-acting neurotoxin candidate. The agency cited manufacturing-related issues and raised no safety or efficacy concerns, but the delay still pushes back a potential new product launch. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE
• Negative Sentiment: AbbVie also terminated its deal with I-Mab to develop a cancer drug, removing a potential pipeline opportunity and signaling a setback in its oncology collaboration strategy. AbbVie terminates deal with I-Mab to develop cancer drug

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $240.00 price target on shares of AbbVie in a research note on Thursday, April 30th. Evercore set a $235.00 price target on AbbVie in a research note on Friday, May 15th. Canaccord Genuity Group boosted their price target on AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. William Blair restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Guggenheim restated a “buy” rating and issued a $249.00 price target on shares of AbbVie in a research note on Friday, May 1st. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $253.43.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.